Our Team gathers scientific experts in bone diseases, in cartilage mechanistics, in skin inflammation and pathologies, in oncology, in toxicology, in histopathology… Also trained technicians and QA Team to ensure robustness and traceability for your non regulatory studies.
Our scientific board and our local & international networks are also a strength to support you in your preclinical research and early-stage programs keeping a solution-oriented mindset.
With a strong relationship and weekly reporting, we optimize the results and interpretation using what you know on your products and what we know on our models and techniques. You are warmely welcome to visit us on our site, meet our Team, discuss your programs and visit our labs.
With an international sales manager training, Arnaud has been evolving in several sectors such as quality control, building trade and food industry. His role in ABS Team is to develop partnership and business with both academic and industrial Partners, all around the world.
Benjamin has received his PhD thanks to research on hyaluric acid in Claude Bernard University in Lyon, France. He has been especially working on hyaluronic acid impact on inflammation in dermatology. He has been developing both vitro and vivo models in order to evaluate candidates for skin diseases. Benjamin has thus a strong expertise in dermocosmetic, inflammation, skin testing and histology.
With a Master’s degree in Human Resources Management from IAE Nantes, Coline YVON first worked in a general HR role in the banking insurance sector before joining the AtlAntA Group in January 2024
Elodie received her PhD from the University of Clermont Ferrand in neuropharmacology of pain, dedicated to the study of chronic pain in murine models of Arthritis and IBS.
After 2 postdoctoral positions in the Institut Pasteur in Lille, focused on chronic inflammatory diseases such as COPD and NASH, she was Study Director in Safety Pharmacology and Toxicology in an European CRO, before joining our Team.
Julie has a professional degree in Health biotechnology. Before joining us, she worked for 5 years in the INSERM Laboratory Physiopathology of bone resorption and therapy of primary bone tumors.
After having worked has a technician on our histology platform, she has acceded to the Project Manager role thanks to her expertise and volontee to be in direct contact with our Customers and support them with robust and reliable results in respect with their specifications and time constraints.
Malo received his PhD from the University of Nantes in 2020 after 3 years of thesis in biology, dedicated to the study of new strategies for immune tolerance induction in transplantation. He then worked as a Research Engineer in an academic laboratory, with a particular focus on the microscopic description of the neuromuscular junction in pathological contexts; before joining Atlantic Bone screen in December 2022 as a project manager. His different missions allowed him to develop a strong expertise in microscopy and image analysis.
First obtaining his PhD in Nancy on nanoparticule to target osteoarticular applications, Mathieu has then moved to Dublin where he has realised his postdoc working on various pathways involved in the translation of mechanical signals into biological responses, with a particular focus on bone tissue. He has also been appointed as a Lab Manager at the Trinity Center for Biomedical engineering before joining ATLANTIC BONE SCREEN.
Paola has a MSc in Molecular and Cellular Biology from the University of Rome Tor Vergata and obtained her PhD from the Centre for Biomedical Engineering of the Trinity College of Dublin. Her project focused on the mechanism behind the chondrogenesis of adult stem cells for cartilage tissue engineering applications. In particular, she studied stem cells mechanosensation in response to biomaterials and external mechanical cues. After having obtained her PhD, Paola joined an INSERM laboratory in Paris for a 3-years postdoc project focusing on the development, characterization and industrialization of a medical device for bone regeneration. As Project Manager, she is committed to providing high value scientific advices to our customers as well as robust and reliable results in respect with their specifications and time constraints.
Quitterie BROSSARD has Biotech Engineer diplom and combines scientific and business development skills thanks to a master in "Quality, Management and Business" and thanks to her experience in Life Sciences and Biotechnologies market for the last 15 years. She is now in charge of the Sales Team and of the international business development at Altantic Bone Screen.
As a Pharmacist specialized in Quality management, Romain has been working in food and health domains for several years as Quality assurance and regulatory affairs Manager. After more than 12 years in a contract manufacturer company, Romain has joined AtlAntA group in August 2023 as a Quality Assurance Manager (QAM). In a continuous quality improvement initiative, his role is to make QS live and evolve by keeping in considerations our customers needs, our strategy and ISO9001 standards.
After receiving his Doctor of Pharmacy, Ronan LE BOT started his career in the industry. A variety of professional experiences and more particularly with AVENTIS allowed him to gain a highly-specialized expertise in preclinical evaluation of drug candidates. After joining the “Institut d’Administration des Entreprises” (Business Administration Institute), he founded his first CRO (Atlantic Bone Screen, 2005) then developed a subsidiary with another CRO AtlanChim Pharma (2008) before setting up a Research & Development company (Atlanthéra, 2009) and to federate all the companies under the AtlAntA group in 2011.
Victoria holds an Engineer degree in Biology from the National Institute of Applied Sciences (INSA) along with a master specialized in business development and entrepreneurship from the Toulouse Business School (TBS). After several years of experience in business and marketing, in private company and in CRO, she has joined Atlantic Bone Screen in January 2023 to fully dedicate herself to business development while working in a highly scientific field.